DuPont Extends its Costa Rica Healthcare Manufacturing Facility

DuPont de Nemours, Inc. (NYSE:DD) is among the 13 Best Hydrogen and Fuel Cell Stocks to Buy According to Analysts. It has added 16,000 square feet of operational space to its healthcare manufacturing facility in Heredia, Costa Rica.

A closeup of a hand manipulating a complex piece of machinery in a semiconductor factory.

This supports DuPont de Nemours, Inc. (NYSE:DD)’s global medical device supply chain and is the first sterile healthcare packaging operation in Costa Rica and the Caribbean. The facility now runs around the clock, creating sterile packaging made of Tyvek®, including lids, header bags, and pouches, and expanding its capacity for medical tubing.

This development improves DuPont de Nemours, Inc. (NYSE:DD)’s sterile operations and extrusion capabilities throughout the Americas, solidifying the company’s position in the healthcare industry. The expansion of the Heredia website reflects the rising need for superior sterile packaging and fluid management supplies.

According to James Chambers, SVP and General Manager of Spectrum Plastics Group, a DuPont company, this action is evidence of DuPont de Nemours, Inc. (NYSE:DD)’s position as a reliable worldwide partner in the medical manufacturing industry.

DuPont de Nemours, Inc. (NYSE:DD)’s portfolio now includes Spectrum Plastics, which was acquired in August 2023 and brings more than 60 years of experience in polymer processing and device production.

Furthermore, the company produces PEM fuel cells, which are essential for electrolyzers that separate hydrogen and oxygen.

While we acknowledge the potential of DD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.